Open access
Open access
Powered by Google Translator Translator

RCT: Similar outcomes with 5 vs. 2 years of zoledronate treatment following adjuvant chemotherapy in early breast cancer.

1 Jul, 2021 | 09:50h | UTC

Outcomes With 5 vs 2 Years of Zoledronate Treatment Following Adjuvant Chemotherapy in Early Breast Cancer – The ASCO Post

Original Study: Prognosis of Patients With Early Breast Cancer Receiving 5 Years vs 2 Years of Adjuvant Bisphosphonate Treatment: A Phase 3 Randomized Clinical Trial – JAMA Oncology (link to abstract – $ for full-text)

 


Stay Updated in Your Specialty

No spam, just news.